LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_006231.4:c.62+9C>T
POLE
· NP_006222.2:p.?
· NM_006231.4
GRCh37: chr12:133263831 G>A
·
GRCh38: chr12:132687245 G>A
Gene:
POLE
Transcript:
NM_006231.4
Final call
VUS
PM2 moderate
Variant details
Gene
POLE
Transcript
NM_006231.4
Protein
NP_006222.2:p.?
gnomAD AF
6.758967121680333e-07 (v4.1)
ClinVar
Likely benign
OncoKB
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PM2 Moderate: the highest relevant allele frequency is 1.04e-5, below the supplied 0.0001 cutoff, with one allele and no homozygotes.
Final determination:
Under the local POLE framework's ACMG/AMP combination rules, PM2 Moderate alone satisfies no pathogenic, likely pathogenic, benign, or likely benign rule, resulting in VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.62+9C>T is an intronic substitution outside the PVS1-named null-variant classes, including canonical ±1/2 splice sites, and has protein consequence p.? . |
pvs1_variant_assessment
pvs1_gene_context
|
| PS1 | N/A | Not applicable: the intronic c.62+9C>T variant has protein consequence p.?, so no same-amino-acid substitution exists for comparison. |
|
| PS2 | Not assessed | Not assessed: no documented affected proband, family history, or confirmed maternity and paternity for this variant. |
|
| PS3 | Not assessed | Not assessed: no variant-specific validated in vitro or in vivo functional assay result is available to establish a damaging effect. |
|
| PS4 | Not met | Not met: the POLE rule requires an exact recurrent missense hotspot with combined endometrial-cancer count >=10, but this intronic c.62+9C>T variant is not listed. |
vcep_path_250_323
vcep_path_250_323_s002
vcep_path_250_323_s001
|
| PM1 | N/A | Not applicable: the POLE framework restricts PM1 to exact exonuclease-domain missense substitutions, while c.62+9C>T is intronic and p.? . |
vcep_path_250_323
vcep_path_250_323_s002
vcep_path_250_323_s001
|
| PM2 | Met | Met at Moderate: the highest relevant AF is 1.04e-5, below the supplied 0.0001 PM2 cutoff, with one allele and no homozygotes. |
gnomad_v2
gnomad_v4
|
| PM3 | Not assessed | Not assessed: no affected-proband observation or parental/offspring testing establishes this variant in trans with a pathogenic variant. |
|
| PM4 | N/A | Not applicable: c.62+9C>T is an intronic single-nucleotide substitution with protein consequence p.?, not a documented in-frame indel or stop-loss variant. |
pvs1_variant_assessment
|
| PM5 | N/A | Not applicable: the intronic c.62+9C>T variant has protein consequence p.?, so PM5 cannot compare alternate missense changes at one residue. |
|
| PM6 | Not assessed | Not assessed: no affected patient with an assumed de novo variant and incomplete parental testing is documented. |
|
| PP1 | Not assessed | Not assessed: no affected relatives or informative variant segregation data are documented for evaluating co-segregation. |
|
| PP2 | N/A | Not applicable: PP2 is restricted to missense variants, whereas c.62+9C>T is intronic and produces protein consequence p.?. |
|
| PP3 | N/A | Not applicable: the POLE PP3 rule is restricted to exact missense variants, whereas c.62+9C>T is intronic with predicted protein consequence p.?. |
vcep_path_250_323
vcep_path_250_323_s002
vcep_path_250_323_s003
vcep_path_250_323_s004
|
| PP4 | Not assessed | Not assessed: no patient phenotype or family-history details were available to test the PP4 specificity requirement. |
|
| PP5 | Not met | Not met: ClinVar has one single-submitter Likely benign record and zero expert-panel submissions, not an expert-panel Pathogenic or Likely pathogenic classification. |
clinvar
PMID:28492532
|
| BA1 | Not met | Not met: observed allele frequencies are 6.76e-7 to 1.04e-5, far below the 0.05 BA1 threshold. |
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the highest observed AF is 1.04e-5, below the supplied 0.01 BS1 default and not greater than expected for the disorder. |
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: no homozygotes were observed, but the single carrier is not documented as a healthy adult under a fully penetrant early-onset disease model. |
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no variant-specific validated in vitro or in vivo functional assay result is available to establish a non-damaging effect. |
|
| BS4 | Not assessed | Not assessed: no affected relatives lacking the variant are documented to demonstrate absence of segregation. |
|
| BP1 | N/A | Not applicable: BP1 is restricted to missense variants, whereas c.62+9C>T is intronic and produces protein consequence p.?. |
|
| BP2 | Not assessed | Not assessed: no phase data establish this variant in trans or cis with a pathogenic variant. |
|
| BP3 | N/A | Not applicable: c.62+9C>T is an intronic single-nucleotide substitution, not an in-frame deletion or insertion in a repetitive region without known function. |
pvs1_variant_assessment
|
| BP4 | N/A | Not applicable: the POLE BP4 rule is restricted to exact missense variants, whereas c.62+9C>T is intronic with predicted protein consequence p.?. |
vcep_path_250_323
vcep_path_250_323_s002
vcep_path_250_323_s003
vcep_path_250_323_s004
|
| BP5 | Not assessed | Not assessed: no affected case with an independently established alternate molecular basis for disease was available. |
clinvar
|
| BP6 | Not met | Not met: the exact ClinVar record is single-submitter Likely benign with zero expert-panel submissions, so it does not satisfy the BP6 evidence requirement. |
clinvar
PMID:28492532
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, but c.62+9C>T is intronic and has predicted protein consequence p.?. |
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.